Qualigen Therapeutics stock soars after patent grants across 25 countries

Published 16/07/2025, 13:32
© Reuters.

Investing.com -- Qualigen Therapeutics (NASDAQ:QLGN) stock surged 80% after the company announced it has been granted new patents covering 25 countries for its cancer drug QN-302.

The patents, titled "Substituted Naphthalene Diimides and Their Use," cover the product and manufacturing methods for QN-302, a drug developed by Professor Stephen Neidle and his team at University College London and licensed by Qualigen. The patent protection extends into 2040.

Through validations across Europe, the patents now cover over 20 European countries, representing the majority of the European population. Additionally, Qualigen has secured similar patent coverage in India, China, and Russia.

"Having the patents granted covering so much of the world’s population strengthens our position as a drug development company. By assuring such strong coverage will allow us to continue bringing QN-302 to market and treating patients suffering from Pancreatic and Gastrointestinal Cancer," stated Kevin Richardson II, CEO of Qualigen.

QN-302 is being developed for the treatment of pancreatic and gastrointestinal cancers. The company indicated it will provide periodic updates on additional patents as they are granted, noting that several have been published while others remain pending.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.